Literature DB >> 7950978

Adenosine A2B receptor signalling is altered by stimulation of bradykinin or interleukin receptors in astroglioma cells.

B B Fredholm1, N Altiok.   

Abstract

The human astroglioma cell D384 possesses adenosine A2B receptors coupled to the formation of cyclic AMP. These cells also possess bradykinin B2 receptors coupled to phospholipase C and consequent increases in intracellular calcium and protein kinase C. Interleukin 1 beta causes an increase in c-fos, AP-1 transcriptional activity and an increased expression of several genes including NGF, but the initial signalling events are unknown. Bradykinin causes a rapid decrease in A2B receptor mediated cAMP formation, via a mechanism that involves calcium, but not cGMP, and appears to depend upon a direct decrease in adenylyl cyclase. Il-1 beta causes a slowly developing (18-24 h) increase in A2B receptor signalling. The results indicate that adenosine effects in glial cells, believed to be important in neuroprotection, are modified in the short and long-term by inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7950978     DOI: 10.1016/0197-0186(94)90060-4

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  3 in total

1.  Astrocytic and neuronal localization of the scaffold protein Na+/H+ exchanger regulatory factor 2 (NHERF-2) in mouse brain.

Authors:  Maryse Paquet; Masaaki Kuwajima; C Chris Yun; Yoland Smith; Randy A Hall
Journal:  J Comp Neurol       Date:  2006-02-10       Impact factor: 3.215

2.  Interaction of adenosine and guanine derivatives in the rat hippocampus: effects on cyclic AMP levels and on the binding of adenosine analogues and GMP.

Authors:  C I Tasca; D O Souza
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

Review 3.  Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson's disease and its treatment.

Authors:  Dasiel O Borroto-Escuela; Kjell Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.